Gene Editing Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Component (Reagents and Consumables, Software and Systems, and Services), Technology (Clustered Regularly Interspaced Short Palindromic Repeats, Transcription Activator-Like Effector Nucleases, Zinc Finger Nucleases, and Other Technologies), Application (Genetic Engineering and Clinical Applications), End User (Pharmaceutical companies and Biotechnology Companies, Academics and Government Research Institutes, and Clinical Research Organizations), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Market Report I 2023-12-05 I 150 Pages I The Insight Partners
The gene editing market size is expected to grow from US$ 6.542 billion in 2022 to US$ 23.902 billion by 2030; it is estimated to record a CAGR of 17.6% during 2022-2030.
The growth of the gene editing market is attributed to the increase in cancer and other genetic disorders and growing investment in genetic research. However, the high cost of genomic equipment hinders the market growth.
Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The ability to make precise changes in the genome opens new possibilities for developing targeted therapies and personalized medicine. Gene editing is crucial in personalized medicine by tailoring medical treatments to individual patients based on their genetic information. It offers various applications in the field. Firstly, gene editing techniques like CRISPR-Cas9 enable the correction or modification of specific genes associated with genetic disorders, potentially providing treatments or cures for conditions such as cystic fibrosis and other genetic disorders. Secondly, gene editing aids in pharmacogenomics, allowing researchers to study how an individual's genetic variation impacts their medication response. This knowledge helps in developing personalized treatment plans and optimizing drug dosage.
Gene editing has also shown promise in personalized cancer therapy, where immune cells can be edited to better target and destroy cancer cells. Furthermore, gene editing can contribute to preventing and treating infectious diseases by enhancing immune cell recognition and modifying pathogens. It also facilitates disease modeling and drug development by creating accurate disease models, enabling researchers to understand diseases better and develop personalized treatment approaches. These applications demonstrate the potential of gene editing in advancing personalized medicine, enabling tailored treatments specific to an individual genetic profile. Gene editing in personalized medicine is still advancing, and further research and clinical trials are needed to ensure safety and efficacy.
The growing need for personalized medicine is one of the main factors propelling the growth of the gene editing market. Gene editing technology makes customized therapies and treatments based on an individual's genetic composition possible. In July 2021, the US FDA authorized one patient to receive a tailored CRISPR-based gene therapy for their mutation. The Boston non-profit Cure Rare Disease initiated the clinical trial, which marked numerous milestones, including the first-ever personalized CRISPR therapy and the first clinical trial to implement any form of gene editing for muscular dystrophy treatment.
Increased patient well-being, fewer adverse effects, and better treatment outcomes are all possible with this personalized approach to medicine. The demand for targeted therapeutics and the increasing understanding of personalized medicine have been major factors in the uptake and development of gene editing technology. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and treating previously incurable diseases, favoring market growth.
The cost of production is determined by the packages of genome editing for different applications offered by different players. The costs associated with gene editing equipment can be substantial. Gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, fluorescence microscopes, and electroporation devices. These instruments have a high price tag, ranging from thousands to millions of dollars. The US Food and Drug Administration (FDA) has authorized four gene treatments. Kymriah and Yescarta are two chimeric antigen receptor (CAR T-cell) treatments. Yescarta costs US$ 373,000 in the market, whereas Kymriah costs between US$ 373,000 and US$ 475,000, depending on the kind of cancer. The FDA licensed Luxturna in 2017 to treat a rare kind of inherited blindness that affects 1,000 to 2,000 people in the US. The cost of this procedure is US$ 425,000 per eye. Zolgensma was licensed in 2020 to treat a rare childhood condition called spinal muscular atrophy in children under the age of two. Per patient, a single intravenous injection costs US$ 2.1 million. The cost of production is increased based on the procedures added during the production.
In addition, additional challenges and costs are associated with the validation and evaluation of genome editing methods. If the validation shows negative results, repetitive procedures are performed, and hundreds and thousands of dollars are spent on the same procedures. Thus, out of the total cost incurred in the production of genome editing, two-thirds is spent on validation. Hence, the cost of production is among the primary factors restraining the market's growth.
Components-Based Insights
Based on components, the gene editing market is segmented into reagents and consumables, software and systems, and services. The services segment dominated with the largest share of the market in 2022. However, the reagents and consumables segment is anticipated to register the highest CAGR from 2022 to 2030.
The International Agency for Research on Cancer and the World Health Organization (WHO) are among the primary and secondary sources referred to while preparing the gene editing market report.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Gene Editing Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Gene Editing Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Gene Editing Market - Global Market Analysis
6.1 Gene Editing - Global Market Overview
6.2 Gene Editing - Global Market and Forecast to 2030
7. Gene Editing Market - Revenue Analysis (USD Million) - By Technology, 2020-2030
7.1 Overview
7.2 Clustered Regularly Interspaced Short Palindromic Repeats
7.3 Transcription Activator-Like Effector Nucleases
7.4 Zinc Finger Nucleases
7.5 Other Technologies
8. Gene Editing Market - Revenue Analysis (USD Million) - By Component, 2020-2030
8.1 Overview
8.2 Reagents and Consumables
8.3 Software and Systems
8.4 Services
9. Gene Editing Market - Revenue Analysis (USD Million) - By Application, 2020-2030
9.1 Overview
9.2 Clinical Applications
9.3 Genetic Engineering
10. Gene Editing Market - Revenue Analysis (USD Million) - By End User, 2020-2030
10.1 Overview
10.2 Pharmaceutical Companies and Biotechnology Companies
10.3 Academics and Government Research Institutes
10.4 Clinical Research Organizations
11. Gene Editing Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis
11.1 North America
11.1.1 North America Gene Editing Market Overview
11.1.2 North America Gene Editing Market Revenue and Forecasts to 2030
11.1.3 North America Gene Editing Market Revenue and Forecasts and Analysis - By Technology
11.1.4 North America Gene Editing Market Revenue and Forecasts and Analysis - By Component
11.1.5 North America Gene Editing Market Revenue and Forecasts and Analysis - By Application
11.1.6 North America Gene Editing Market Revenue and Forecasts and Analysis - By End User
11.1.7 North America Gene Editing Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Gene Editing Market
11.1.7.1.1 United States Gene Editing Market, by Technology
11.1.7.1.2 United States Gene Editing Market, by Component
11.1.7.1.3 United States Gene Editing Market, by Application
11.1.7.1.4 United States Gene Editing Market, by End User
11.1.7.2 Canada Gene Editing Market
11.1.7.2.1 Canada Gene Editing Market, by Technology
11.1.7.2.2 Canada Gene Editing Market, by Component
11.1.7.2.3 Canada Gene Editing Market, by Application
11.1.7.2.4 Canada Gene Editing Market, by End User
11.1.7.3 Mexico Gene Editing Market
11.1.7.3.1 Mexico Gene Editing Market, by Technology
11.1.7.3.2 Mexico Gene Editing Market, by Component
11.1.7.3.3 Mexico Gene Editing Market, by Application
11.1.7.3.4 Mexico Gene Editing Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Gene Editing Market - Key Company Profiles
14.1 Thermo Fisher Scientific Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Merck KGaA
14.3 Lonza
14.4 GenScript
14.5 CRISPR Therapeutics
14.6 PerkinElmer Inc.
14.7 Agilent Technologies
14.8 Precision BioSciences
14.9 Sangamo Therapeutics Inc.
14.10 New England Biolabs
14.11 Novartis
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.